Promising drugs being developed to prevent eventual failure of hormone therapy for prostate cancer
October 30, 2009 by Jim Tucker
URO TODAY: Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness, and two new drugs are showing promise in preventing that happen. READ MORE>
Notably, promising activity has been shown in early phase trials by MDV3100, a new anti-androgen designed for activity in prostate cancer model systems with over-expressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks steroid biosynthesis in the adrenal gland and possibly within the tumour. Both agents are undergoing phase three testing.
Like this:
Like Loading...
Posted in Hormone therapy, Hormone-refactory, PROSTATE CANCER, PROSTATE RESEARCH, Treatment news | Tagged abiraterone acetate, adrenal gland, advanced prostate cancer, androgen receptor, cancer research, CYP17A inhibitor, early phase trials, Hormone therapy, MDV3100, new anti-androgen, over-expressed androgen receptor, phase three testing, prostablog, prostate, prostate blog, prostate cancer growth, prostate cancer treatments, prostate treatment, prostate treatment debate, steroid biosynthesis, URO TODAY | Leave a Comment
Prostablog 
Leave a Reply